Earnings
Dr. Reddy's CEO Says Semaglutide API Problem Is Solved, But Drug Validation Is Still Pending
Erez Israeli says orders are in hand for a November relaunch, with most volume headed to Canada.
RDY
Dr. Reddy's Laboratories (RDY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Dr. Reddy's CEO Concedes FDA Could Still Reject Its Abatacept Biosimilar: 'There Is A Chance'
Erez Israeli says the company is preparing a December US launch and sees a 15% to 25% share for the intravenous version.
SEC Filings
Dr. Reddy's Gets India Nod For Zytorvi In Esophageal Cancer, Citing 42% Lower Risk Of Disease Or Death
The company's immunotherapy now has a second approved use in India, with survival of 17.7 months versus 12.9 on chemotherapy alone.